172 related articles for article (PubMed ID: 22549171)
21. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
L'Hermite M
Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
[TBL] [Abstract][Full Text] [Related]
22. Risk of venous thromboembolism by route of administration of estrogen.
Lobo RA
Menopause; 2011 May; 18(5):469-70. PubMed ID: 21407136
[No Abstract] [Full Text] [Related]
23. A current perspective into young female sex hormone replacement: a review.
Giordano Imbroll M; Gruppetta M
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):405-414. PubMed ID: 32893689
[TBL] [Abstract][Full Text] [Related]
24. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
[TBL] [Abstract][Full Text] [Related]
25. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
Canonico M; Plu-Bureau G; Scarabin PY
Maturitas; 2011 Dec; 70(4):354-60. PubMed ID: 22024394
[TBL] [Abstract][Full Text] [Related]
26. Oestrogens and progestins and breast cancer risk in post-menopausal women.
La Vecchia C
Pharmacol Res; 1995 Dec; 32(6):323-4. PubMed ID: 8736479
[No Abstract] [Full Text] [Related]
27. Aortic hemodynamics in postmenopausal women following cessation of hormone therapy.
Harvey RE; Johnson MC; Ranadive SM; Joyner MJ; Lahr BD; Miller VM; Barnes JN
Physiol Rep; 2017 Dec; 5(23):. PubMed ID: 29208690
[TBL] [Abstract][Full Text] [Related]
28. Letter by Micheletti and Chevallier regarding article, "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study".
Micheletti MC; Chevallier T
Circulation; 2007 Sep; 116(13):e362; author reply e363. PubMed ID: 17893283
[No Abstract] [Full Text] [Related]
29. A modern approach to postmenopausal HRT: trading bleeding with safety.
Al-Azzawi F; Wahab M
Womens Health (Lond); 2012 Jan; 8(1):1-4. PubMed ID: 22171766
[No Abstract] [Full Text] [Related]
30. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Połać I; Borowiecka M; Wilamowska A; Nowak P
Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237
[TBL] [Abstract][Full Text] [Related]
31. Hormone therapy and venous thromboembolism.
Peverill RE
Best Pract Res Clin Endocrinol Metab; 2003 Mar; 17(1):149-64. PubMed ID: 12763518
[TBL] [Abstract][Full Text] [Related]
32. Increased coronary events, HERS, and HRT: any connection?
Rebar RW; Archer D
Arch Intern Med; 2001 May; 161(10):1350-1. PubMed ID: 11371266
[No Abstract] [Full Text] [Related]
33. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003?
Canonico M; Scarabin PY
Menopause; 2016 Jun; 23(6):587-8. PubMed ID: 27116463
[No Abstract] [Full Text] [Related]
34. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
Davey DA
Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
[TBL] [Abstract][Full Text] [Related]
35. EMAS position statement: Managing menopausal women with a personal or family history of VTE.
Tremollieres F; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Vujovic S; Rozenberg S; Rees M;
Maturitas; 2011 Jun; 69(2):195-8. PubMed ID: 21489728
[TBL] [Abstract][Full Text] [Related]
36. Genetic influence of hormone-replacement therapy on venous thromboembolism.
Sumino H; Ichikawa S; Kumakura H; Takayama Y; Kurabayashi M
Lancet; 2003 Oct; 362(9391):1242. PubMed ID: 14568759
[No Abstract] [Full Text] [Related]
37. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
Simon JA; Laliberté F; Duh MS; Pilon D; Kahler KH; Nyirady J; Davis PJ; Lefebvre P
Menopause; 2016 Jun; 23(6):600-10. PubMed ID: 26953655
[TBL] [Abstract][Full Text] [Related]
38. Menopausal hormone therapy and risk of venous thromboembolism: The story so far.
Abdelhafez MMA; Ahmed KAM; Ahmed NAM; Ismail MH; Daud MNM; Eldiasty AME; Amri MFB; Jeffree MS; Masnah FK; Baharuddin DMP; Bolong MF; Hayati MF; Azizan NB; Sumpat D; Abdul Rahim SSS; Than WW; Ibrahim MY; Lo ZZ; Soe MZ
Afr J Reprod Health; 2024 Mar; 28(3):122-129. PubMed ID: 38583076
[TBL] [Abstract][Full Text] [Related]
39. Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the Nurses' Health Study.
Herd JA; Gotto AM
Pharmacol Res; 1995 Dec; 32(6):331-3. PubMed ID: 8736483
[No Abstract] [Full Text] [Related]
40. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
